TAMPA, Fla.--(BUSINESS WIRE)--Scientists for Nanobac Pharmaceuticals Inc. (OTCBB:NNBP) (“Nanobac” or “the Company”) have published a new outlook on the role of calcifying nanoparticles (CNPs) in diseases such as atherosclerosis and kidney stones, setting the groundwork for what company officials call a “significant” announcement next week.
